DANVILLE, Calif., May 15, 2017 /PRNewswire/ -- Palo Alto Health Sciences, Inc. (PAHS), developer of Freespira®, the only FDA-cleared digital therapeutic for panic attacks and symptoms of panic disorder, today announced that clinical results from the most recent trial will be presented at the Clinical Transcranial Magnetic Stimulation Society (CTMSS) Annual Meeting on May 19th in San Diego.
Principal investigator David Tolin, PhD, Director of the Anxiety Disorders Center, The Institute of Living and Adjunct Professor of Psychiatry at Yale University School of Medicine, will present a poster titled A Multisite Benchmarking Trial of Capnometry Guided Respiratory Intervention for Panic Disorder in Naturalistic Treatment Settings.
"Freespira is a validated new treatment option for patients with panic disorder. It is simple, effective, and drug-free, and the results are durable for at least 12 months after treatment is completed. This latest study confirms the results seen in a prior study at a single academic center and, importantly, demonstrates that the Freespira treatment is equally effective and safe when provided in the community setting," commented Dr. Tolin.
Debra Reisenthel CEO of PAHS added, "We are excited to be attending this important conference of clinicians who have adopted leading-edge treatments for mental health conditions. As the only FDA-cleared digital therapeutic for treating panic attacks and panic disorder, Freespira is well-suited for, and can be easily integrated into, practices offering TMS."
Freespira is authorized by a licensed healthcare provider and is both easy to use and effective. After one training session with a technician, the patient takes Freespira home and performs two 17-minute breathing sessions a day over a four-week period, after which the treatment is complete. Patients are remotely monitored and coached by the PAHS practice coordination team during the treatment period. The patient returns to the Clinic post-treatment for a follow-up visit.
About Freespira
Freespira is the only FDA-cleared, non-invasive, medication-free, four-week at-home treatment for panic attacks and other panic symptoms. Treatment is authorized and completed under the supervision of a licensed healthcare provider. Freespira is clinically proven to reduce or eliminate panic attacks and other symptoms of panic disorder, a mental health condition in which debilitating anxiety leads to life-altering avoidance behaviors. Individuals with panic chronically hyperventilate, even when not experiencing a panic attack. This abnormal breathing pattern has been shown to exacerbate attacks. Freespira works by training the patient to stabilize respiration rate and exhaled carbon dioxide levels, which reduces or eliminates panic attacks. The Tolin multi-center Freespira trial demonstrated that 71% of patients were panic-attack free immediately after treatment, and 79% of patients were panic attack free 12 months post-treatment.
About Palo Alto Health Sciences, Inc.
Palo Alto Health Sciences, Inc. is a privately held digital therapeutic company at the forefront of revolutionizing behavioral healthcare with evidence-based, non-invasive, drug-free solutions. The Company's first product, Freespira, is an FDA-cleared treatment for individuals suffering from panic disorder, panic attacks and other symptoms of panic. In the United States, over 6.7 million adults annually suffer from panic disorder; panic attacks affect a total of 27 million adults in the U.S. every year and are a common component of other anxiety disorders.
Freespira is commercially available throughout the U.S. and is currently being evaluated by Anthem and Highmark Health in regional Quality Improvement Programs to assess Freespira's impact in reducing the elevated medical costs of treating patients with panic disorder. To learn more, visit http://www.freespira.com or contact info@pahealthsciences.com.
MEDIA CONTACT
Michele Kong
(800) 735-8995
michele@pahealthsciences.com
SOURCE Palo Alto Health Sciences, Inc.